BR0211358A - Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis - Google Patents

Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis

Info

Publication number
BR0211358A
BR0211358A BR0211358-9A BR0211358A BR0211358A BR 0211358 A BR0211358 A BR 0211358A BR 0211358 A BR0211358 A BR 0211358A BR 0211358 A BR0211358 A BR 0211358A
Authority
BR
Brazil
Prior art keywords
fluorophenyl
physiologically acceptable
pyridylmethylaminomethyl
acceptable salts
compound
Prior art date
Application number
BR0211358-9A
Other languages
English (en)
Inventor
Gerd Bartoszyk
Hermann Russ
Christoph Seyfried
Frank Weber
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BR0211358A publication Critical patent/BR0211358A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USO DO COMPOSTO DE 2-[5-(4-FLUOROFENIL)-3PIRIDILMETILAMINOMETIL]-CROMANO E SEUS SAIS FISIOLOGICAMENTE ACEITáVEIS". A presente invenção refere-se ao uso do composto de (R/S)-(/+)-2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano ou de um sal fisiologicamente aceitável do mesmo e do composto de (S)-(+)-2-[5-(4-fluorofenil)3-piridilmetilaminometil]-cromano ou um sal fisiologicamente aceitável do mesmo para a fabricação de um medicamento destinado ao tratamento de distúrbios do movimento extrapiramidal e/ou tratamento dos efeitos adversos nos distúrbios do movimento extrapiramidal.
BR0211358-9A 2001-07-26 2002-07-10 Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis BR0211358A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01118097 2001-07-26
PCT/EP2002/007660 WO2003009835A2 (en) 2001-07-26 2002-07-10 Novel use of 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane and its physiologically acceptable salts

Publications (1)

Publication Number Publication Date
BR0211358A true BR0211358A (pt) 2004-09-21

Family

ID=8178137

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211358-9A BR0211358A (pt) 2001-07-26 2002-07-10 Uso do composto de 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-croman o e seus sais fisiologicamente aceitáveis

Country Status (24)

Country Link
US (1) US7872030B2 (pt)
EP (1) EP1408964B1 (pt)
JP (1) JP2004538289A (pt)
KR (1) KR20040029325A (pt)
CN (1) CN1292749C (pt)
AR (1) AR037496A1 (pt)
AT (1) ATE352302T1 (pt)
AU (1) AU2002355170B2 (pt)
BR (1) BR0211358A (pt)
CA (1) CA2455621C (pt)
CY (1) CY1107616T1 (pt)
DE (1) DE60217870T2 (pt)
DK (1) DK1408964T3 (pt)
ES (1) ES2280602T3 (pt)
HK (1) HK1068793A1 (pt)
HU (1) HUP0402092A3 (pt)
MX (1) MXPA04000775A (pt)
MY (1) MY134059A (pt)
PE (1) PE20030277A1 (pt)
PL (1) PL208258B1 (pt)
PT (1) PT1408964E (pt)
RU (1) RU2297833C2 (pt)
SI (1) SI1408964T1 (pt)
WO (1) WO2003009835A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565460A (en) 2005-07-26 2011-06-30 Bial Portela & Ca Sa Nitrocatechol derivatives as COMT inhibitors
EP1845097A1 (en) * 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
US8524746B2 (en) 2007-01-31 2013-09-03 Bial-Portela & Ca., S.A. Dosage regimen for COMT inhibitors
AR070907A1 (es) 2008-03-17 2010-05-12 Bial Portela & Ca Sa Formas cristalinas de derivado de nitrocatecol
ES2730678T3 (es) 2009-04-01 2019-11-12 Bial Portela & Ca Sa Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para fabricarlas
CA2931725C (en) 2009-09-11 2021-10-19 Ionis Pharmaceuticals, Inc. Modulation of huntingtin expression
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
HUE047856T2 (hu) 2011-12-13 2020-05-28 Bial Portela & Ca Sa Kémiai vegyület, amely köztitermékként használható katechol-O-metil-transzferáz inhibitor elõállításához
WO2016083863A1 (en) 2014-11-28 2016-06-02 Bial - Portela & Ca, S.A. Medicaments for slowing parkinson's disease

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US576132A (en) * 1897-02-02 Current water-wheel
DE2364685C3 (de) 1973-12-27 1978-06-15 Beiersdorf Ag, 2000 Hamburg Phenoxyäthylamine
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
CA1337429C (en) 1983-12-05 1995-10-24 Guy Rosalia Eugene Van Lommen Derivatives of 2,2'-iminobisethanol
SE460947B (sv) * 1986-08-26 1989-12-11 Lejus Medical Ab En multiple-unit-dos komposition av l-dopa
DE3901814A1 (de) 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
DE69123090D1 (de) 1990-07-06 1996-12-19 Yoshitomi Pharmaceutical Kondensierte Thiophenverbindungen und deren Verwendung
DE4135474A1 (de) 1991-10-28 1993-04-29 Bayer Ag 2-aminomethyl-chromane
US5314888A (en) 1992-02-21 1994-05-24 Trustees Of Tufts College Veterinary method for treating inappropriate elimination of urine in household pets
SI9300097B (en) 1992-02-27 2001-12-31 Janssen Pharmaceutica Nv (benzodioxan, benzofuran or benzopyran) alkylamino) alkyl substituted guanidines
JPH07507058A (ja) 1992-03-11 1995-08-03 インターニューロン　ファーマシューティカルズ，インコーポレーテッド 大型の中性アミノ酸（ｌｎａａ）の血中濃度の食後変動の低減
DE4226527A1 (de) 1992-08-11 1994-02-17 Merck Patent Gmbh 1,4-Benzodioxanderivate
GB9302622D0 (en) 1993-02-10 1993-03-24 Wellcome Found Heteroaromatic compounds
IL114027A (en) 1994-06-08 1999-11-30 Lundbeck & Co As H 4-Phenyl piperazine (piperidine or tetrahydropyridine) derivatives serotinin 5-HT1A and dopamin D2 receptor ligand pharmaceutical compositions containing them
SI0707007T1 (en) * 1994-10-14 2002-04-30 Merck Patent Gmbh (R)-(-)-2-(5-(4-fluorophenyl)-3-pyridylmethylaminomethyl)chromane as CNS active agent
US5502080A (en) 1994-11-01 1996-03-26 Hitzig; Pietr Combined use of dopamine and serotonin agonists in the treatment of allergic disorders
US5554383A (en) 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
US5541199A (en) * 1995-06-02 1996-07-30 American Home Products Corporation Chroman-2-ylmethylamino derivatives
AU6517196A (en) 1995-07-13 1997-02-10 Knoll Aktiengesellschaft Piperazine derivatives as therapeutic agents
GB9514380D0 (en) 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
US5670667A (en) 1995-07-25 1997-09-23 American Home Products Corporation Chroman-2-ylmethylamino derivatives
US5756521A (en) 1996-04-03 1998-05-26 American Home Products Corporation Chroman-2-ylmethylamino derivatives
DE19648384A1 (de) 1996-11-22 1998-05-28 Merck Patent Gmbh Fluorene, Dibenzofurane und Dibenzothiophene
DE69819266T2 (de) 1997-09-02 2004-07-29 Duphar International Research B.V. Piperidin- und Piperazin Derivate als 5-HT1-Rezeptor-Agonisten
EP0900792B1 (en) 1997-09-02 2003-10-29 Duphar International Research B.V Piperazine and piperidine derivatives as 5-HT1A and dopamine D2-receptor (ant)agonists
DE19751949A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verwendung von substituierten Aminomethyl-Chromanen zur Verhinderung der neuronalen Degeneration und zur Förderung der neuronalen Regeneration
WO1999045906A1 (en) 1998-03-09 1999-09-16 Trustees Of Tufts College Treatment of compulsive behaviours in man and animals
CN1155567C (zh) 1998-04-29 2004-06-30 惠氏公司 抑制精神的吲哚基衍生物
UA71590C2 (en) 1998-11-13 2004-12-15 Duphar Int Res Piperazine and piperidine derivatives
UA73981C2 (en) * 2000-03-10 2005-10-17 Merck Patent Gmbh (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit

Also Published As

Publication number Publication date
US20040171645A1 (en) 2004-09-02
DE60217870D1 (de) 2007-03-15
CN1292749C (zh) 2007-01-03
RU2004105844A (ru) 2005-05-10
CA2455621C (en) 2010-11-16
ATE352302T1 (de) 2007-02-15
PE20030277A1 (es) 2003-03-25
KR20040029325A (ko) 2004-04-06
AR037496A1 (es) 2004-11-17
DK1408964T3 (da) 2007-05-21
US7872030B2 (en) 2011-01-18
PL208258B1 (pl) 2011-04-29
CY1107616T1 (el) 2013-03-13
WO2003009835A3 (en) 2003-08-07
HUP0402092A2 (hu) 2005-02-28
SI1408964T1 (sl) 2007-06-30
RU2297833C2 (ru) 2007-04-27
HUP0402092A3 (en) 2010-06-28
MXPA04000775A (es) 2004-04-20
CA2455621A1 (en) 2003-02-06
WO2003009835A2 (en) 2003-02-06
CN1535150A (zh) 2004-10-06
PT1408964E (pt) 2007-05-31
MY134059A (en) 2007-11-30
EP1408964A2 (en) 2004-04-21
HK1068793A1 (en) 2005-07-29
AU2002355170B2 (en) 2007-06-07
PL367291A1 (en) 2005-02-21
JP2004538289A (ja) 2004-12-24
EP1408964B1 (en) 2007-01-24
DE60217870T2 (de) 2007-11-15
ES2280602T3 (es) 2007-09-16

Similar Documents

Publication Publication Date Title
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
BRPI0413555A (pt) composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, método para o tratamento de uma doença, para a fabricação de um composto e para a preparação de composto
NO20025450D0 (no) Ny farmasöytisk sammensetning
PT1040830E (pt) Medicamento para doencas neurodegenerativas
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
BR0307050A (pt) Composto, composição farmacêutica, métodos para o tratamento de doenças mediadas por prostaglandina d2, para o tratamento de congestão nasal, para o tratamento de asma alérgica, e para o tratamento de rinite alérgica, sal farmaceuticamente aceitável, e, uso de um composto ou sal
BR0308901A (pt) ácidos bisfosfÈnicos para tratamento e prevenção de osteoporose
BR0316458A (pt) Composto, composição farmacêutica, método de tratamento ou prevenção de doenças, método para intensificar a cognição em um paciente saudável, e, uso de um composto
CY1107616T1 (el) Καινοτομος χρηση της 2-[5-(4-φθοροφαινυλο)-3-πυριδυλομεθυλαμινομεθυλο]-χρωμανης και των φυσιολογικα αποδεκτων αλατων της
BR0113590A (pt) 7-oxo-piridopirimidinas
DK0669912T3 (da) N-(3-Piperidinylcarbonyl)-beta-alaninderivater som PAF-antagonister
BR0211635A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de um indivìduo sofrendo de ou propenso à doença de alzheimer
BR0109119A (pt) Uso de (r)-(-)-2-[5-(4-fluorofenil)-3-piridilmetil-aminometil]-cr omano e seus sais fisiologicamente aceitáveis
BR0318659A (pt) derivados de prolina usados como ingredientes farmacêuticos ativos no tratamento de tumores
TR200103561T2 (tr) Rodanin türevleri ve amiloidlerin önlenmesi ve görüntülenmesinde kullanımları
ES2173977T3 (es) Uso de r-(z)-alfa-(metoxiimino)-alfa-(1-azabiciclo(2.2.2)oct-3-il)acetonitrilo para reducir la formacion de la proteina amilacea beta a4 en la enfermedad de alzheimer.
BR0209985A (pt) Composto e método para o tratamento de um paciente
DK0420798T3 (da) Antimikrobielle præparater
BR9916244A (pt) Utilização do riluzol ou de um de seus sais farmaceuticamente aceitáveis
BR9915292A (pt) Associação, utilização de riluzol e composição farmacêutica.
BR0317425A (pt) Sal de rabeprazol, composição farmacêutica contendo o mesmo e processo para sua preparação
BR0316823A (pt) Uso de levocetirizina ou um sal desta farmaceuticamente aceitável
BR0212199A (pt) Uso de aminometil cromanos substituìdos no tratamento de distúrbios do movimento
ES2109937T3 (es) Uso de hexetidina o sus derivados o sales para la preparacion de una composicion farmaceutica para uso oftalmico.
BR0303384A (pt) Citalopram e seus usos no tratamento de pressão sanguìnea elevada

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.